Last updated: February 16, 2026
Product Overview
NDC 51672-4227 corresponds to a medication marketed under the brand "Takhzyro," which contains lanadelumab. Lanadelumab is a monoclonal antibody designed for the prevention of hereditary angioedema (HAE) attacks. Approved by the FDA in 2018, it is administered via subcutaneous injection.
Market Size and Demand Dynamics
The hereditary angioedema (HAE) market is characterized by high unmet needs and limited competition. The primary patient population consists of approximately 10,000-15,000 globally, with the United States accounting for roughly 8,000-10,000 cases, based on data from the US Hereditary Angioedema Association and IMS Health reports[1].
Demand for preventive therapies like lanadelumab is driven by:
- Increasing recognition and diagnosis of HAE.
- A shift from on-demand treatments to prophylactic approaches.
- Adoption among patients with frequent attacks (more than 2 per month).
Market penetration is increasing, especially among patients inadequately managed by previous preventive options, such as C1 esterase inhibitors.
Competitive Landscape
Lanadelumab's main competitors include:
- C1 esterase inhibitors (e.g., Berinert, Cinryze).
- Other monoclonal antibodies like ecallantide (Kalbitor).
Market share distribution indicates lanadelumab capturing approximately 60-70% of the prophylactic HAE marketplace in the US, driven by its subcutaneous administration and sustained attack reduction.
Pricing and Reimbursement
As of 2023, the average wholesale price (AWP) for a 300 mg vial of lanadelumab is approximately $4,500. The typical dosing schedule is 300 mg every 2-4 weeks, totaling around 26 doses annually.
- List price per dose: ~$4,500.
- Annual treatment cost: (~26 doses) around $117,000.
Reimbursement rates vary by insurance and payer, but commercial insurers often negotiate discounts of 20-30%. Medicare Part D coverage applies with patient copay responsibilities typically between $5,000 and $10,000 annually, depending on negotiated rates.
Price Projections
Historical pricing trends show stability in list prices, with occasional adjustments due to inflation or market forces. Future projections estimate:
- Slight price increases annually, averaging 3-5%, driven by inflation and manufacturing costs.
- Enhanced competition or emerging biosimilars could put downward pressure, but none are currently approved or marketed.
By 2025, the estimated average annual treatment cost may reach approximately $125,000, assuming a 3% annual increase. Price sensitivity remains high among payers, emphasizing the importance of negotiating rebates and discounts.
Market Outlook and Revenue Forecasts
Projected revenues for lanadelumab assume steady market growth:
| Year |
Estimated US Patients |
Presumed Market Penetration |
Estimated US Revenue (USD) |
| 2023 |
8,000 |
60% |
$600 million |
| 2024 |
9,000 |
70% |
$700 million |
| 2025 |
10,000 |
75% |
$750 million |
Global expansion, especially in Europe and Asia, could add approximately 20-30% to revenues, depending on regulatory approvals and commercial success.
Regulatory and Pricing Policy Factors
- The US FDA approval set the initial price; subsequent pricing is influenced by value-based negotiations.
- CMS and private insurers push for cost-effectiveness; expensive biologics like lanadelumab remain under pressure to justify high costs with clinical benefits.
Summary
Lanadelumab (NDC 51672-4227) occupies a significant market position in HAE prophylaxis, with high clinical value and stable pricing in the near term. Continued market expansion depends on competitive responses and payer acceptance.
Key Takeaways
- The estimated US annual treatment cost for lanadelumab is approximately $117,000, with slight increases expected annually.
- Market penetration is growing, with potential global revenue reaching over $750 million by 2025.
- Reimbursement negotiations and payer policies significantly influence net pricing.
- No biosimilar competition exists currently, though biosimilar development may impact future pricing.
- Demand is driven by increasing diagnosis rates and shift toward prophylactic treatment strategies.
FAQs
1. What factors could influence the price of lanadelumab in the future?
Price changes depend on emerging biosimilar entries, payer negotiations, clinical development of competitors, and regulatory policies emphasizing cost-effectiveness.
2. How does lanadelumab compare to older HAE treatments in terms of cost?
It is generally more expensive than older plasma-derived or recombinant C1 inhibitors but offers advantages like subcutaneous administration and reduced attack frequency, which may justify the premium.
3. What are the main barriers to market expansion for lanadelumab?
High costs and reimbursement challenges are primary barriers, particularly outside the US. Equally, competition and emerging biosimilars could limit market share.
4. Are there any recent price reductions or rebates in the market?
While list prices are stable, negotiated rebates and discounts are common, especially with large payers, lowering the actual net price.
5. What are the prospects for biosimilar entry?
No biosimilars are currently approved for lanadelumab. The development pipeline is uncertain, but biosimilar approval could significantly alter price and market dynamics after 2025.
Citations
[1] US Hereditary Angioedema Association, 2022. Epidemiology and Market Needs.
